View in EDS HTML Full Text PDF Full Text

Surufatinib plus anti‐PD‐1/PD‐L1 antibody as second‐line therapy for advanced biliary tract cancer: A single‐centre investigator‐initiated trial.

Saved in:
Bibliographic Details
Title: Surufatinib plus anti‐PD‐1/PD‐L1 antibody as second‐line therapy for advanced biliary tract cancer: A single‐centre investigator‐initiated trial.
Authors: Chen, Xinni1 (AUTHOR), Wang, Feng1 (AUTHOR), Cheng, Yuan1 (AUTHOR), Cao, Mengran1 (AUTHOR), Mei, Kuimin1 (AUTHOR), Chu, Xiaoyuan1 (AUTHOR), Dai, Fang1 (AUTHOR), Gong, Xinlei1 (AUTHOR) xinleigong@qq.com
Source: Clinical & Translational Discovery. Feb2026, Vol. 6 Issue 1, p1-11. 11p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: asn
DbLabel: Academic Search Ultimate
An: 192088070
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Surufatinib plus anti‐PD‐1/PD‐L1 antibody as second‐line therapy for advanced biliary tract cancer: A single‐centre investigator‐initiated trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Chen%2C+Xinni%22">Chen, Xinni</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Wang%2C+Feng%22">Wang, Feng</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Cheng%2C+Yuan%22">Cheng, Yuan</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Cao%2C+Mengran%22">Cao, Mengran</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Mei%2C+Kuimin%22">Mei, Kuimin</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Chu%2C+Xiaoyuan%22">Chu, Xiaoyuan</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Dai%2C+Fang%22">Dai, Fang</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Gong%2C+Xinlei%22">Gong, Xinlei</searchLink><relatesTo>1</relatesTo> (AUTHOR)<i> xinleigong@qq.com</i>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Clinical+%26+Translational+Discovery%22">Clinical & Translational Discovery</searchLink>. Feb2026, Vol. 6 Issue 1, p1-11. 11p.
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=192088070
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1002/ctd2.70123
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 11
        StartPage: 1
    Titles:
      – TitleFull: Surufatinib plus anti‐PD‐1/PD‐L1 antibody as second‐line therapy for advanced biliary tract cancer: A single‐centre investigator‐initiated trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Chen, Xinni
      – PersonEntity:
          Name:
            NameFull: Wang, Feng
      – PersonEntity:
          Name:
            NameFull: Cheng, Yuan
      – PersonEntity:
          Name:
            NameFull: Cao, Mengran
      – PersonEntity:
          Name:
            NameFull: Mei, Kuimin
      – PersonEntity:
          Name:
            NameFull: Chu, Xiaoyuan
      – PersonEntity:
          Name:
            NameFull: Dai, Fang
      – PersonEntity:
          Name:
            NameFull: Gong, Xinlei
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 02
              Text: Feb2026
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-print
              Value: 27680622
          Numbering:
            – Type: volume
              Value: 6
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Clinical & Translational Discovery
              Type: main
ResultId 1